[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.DOI:10.3322/caac.21660. Cited in this article [1]

[2]	Fan J, Wang L, Zhang C, et al. PDIA3 driven STAT3/PD-1 signaling promotes M2 TAM polarization and aggravates colorectal cancer progression[J]. Aging(Albany NY), 2024, 16(10):8880-8897.DOI:10.18632/aging.205847. Cited in this article [1]

[3]	Keum N, Giovannucci E. Global burden of colorectal cancer:emerging trends,risk factors and prevention strategies[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(12):713-732.DOI:10.1038/s41575-019-0189-8. Cited in this article [1]

[4]	Mikuła-Pietrasik J, Uruski P, Tykarski A, et al. The peritoneal “soil” for a cancerous “seed”:a comprehensive review of the pathogenesis of intraperitoneal cancer metastases[J]. Cell Mol Life Sci, 2018, 75(3):509-525.DOI:10.1007/s00018-017-2663-1. Cited in this article [1]

[5]	Sellner F, Thalhammer S, Klimpfinger M. Tumour evolution and seed and soil mechanism in pancreatic metastases of renal cell carcinoma[J]. Cancers(Basel), 2021, 13(6):1342.DOI:10.3390/cancers13061342. Cited in this article [1]

[6]	Wang H, Tian T, Zhang J. Tumor-associated macrophages(TAMs) in colorectal cancer(CRC):from mechanism to therapy and prognosis[J]. Int J Mol Sci, 2021, 22(16):8470.DOI:10.3390/ijms22168470. Cited in this article [5]

[7]	Yang M, McKay D, Pollard JW, et al. Diverse functions of macrophages in different tumor microenvironments[J]. Cancer Res, 2018, 78(19):5492-5503.DOI:10.1158/0008-5472.CAN-18-1367. Cited in this article [1]

[8]	Li Y, Chen Z, Han J, et al. Functional and therapeutic significance of tumor-sssociated macrophages in colorectal cancer[J]. Front Oncol, 2022, 12:781233.DOI:10.3389/fonc.2022.781233. Cited in this article [1]

[9]	Gao J, Liang Y, Wang L. Shaping polarization of tumor-associated macrophages in cancer immunotherapy[J]. Front Immunol, 2022, 13:888713.DOI:10.3389/fimmu.2022.888713. Cited in this article [1]

[10]	Chen D, Zhang X, Li Z, et al. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages[J]. Theranostics, 2021, 11(3):1016-1030.DOI:10.7150/thno.51777. Cited in this article [1]

[11]	Kumari N, Choi SH. Tumor-associated macrophages in cancer:recent advancements in cancer nanoimmunotherapies[J]. J Exp Clin Cancer Res, 2022, 41(1):68.DOI:10.1186/s13046-022-02272-x. Cited in this article [2]

[12]	Zhang SY, Song XY, Li Y, et al. Tumor-associated macrophages:a promising target for a cancer immunotherapeutic strategy[J]. Pharmacol Res, 2020, 161:105111.DOI:10.1016/j.phrs.2020.105111. Cited in this article [1]

[13]	Hou S, Zhao Y, Chen J, et al. Tumor-associated macrophages in colorectal cancer metastasis:molecular insights and translational perspectives[J]. J Transl Med, 2024, 22(1):62.DOI:10.1186/s12967-024-04856-x. Cited in this article [5]

[14]	Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis[J]. Cell, 2010, 141(1):39-51.DOI:10.1016/j.cell.2010.03.014. Cited in this article [1]

[15]	Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis[J]. Front Physiol, 2014, 5(5):75.DOI:10.3389/fphys.2014.00075. Cited in this article [1]

[16]	Larionova I, Tuguzbaeva G, Ponomaryova A, et al. Tumor-associated macrophages in human breast,colorectal,lung,ovarian and prostate cancers[J]. Front Oncol, 2020, 10:566511.DOI:10.3389/fonc.2020.566511. Cited in this article [2]

[17]	Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages[J]. J Exp Med, 2015, 212(4):435-445.DOI:10.1084/jem.20150295. Cited in this article [1]

[18]	Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology[J]. Nat Rev Clin Oncol, 2017, 14(7):399-416.DOI:10.1038/nrclinonc.2016.217. Cited in this article [1]

[19]	Sica A, Mantovani A. Macrophage plasticity and polarization:in vivo veritas[J]. J Clin Invest, 2012, 122(3):787-795.DOI:10.1172/JCI59643. Cited in this article [1]

[20]	Yahaya MAF, Lila MAM, Ismail S, et al. Tumour-associated macrophages(TAMs) in colon cancer and how to reeducate them[J]. J Immunol Res, 2019, 2019:2368249.DOI:10.1155/2019/2368249 Cited in this article [2]

[21]

Xiao H, Guo Y, Li B, et al. M2-like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKKβ siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects[J]. ACS Cent Sci, 2020, 6(7):1208-1222.DOI:10.1021/acscentsci.9b01235. Cited in this article [1]

[22]	Kwak T, Wang F, Deng H, et al. Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer[J]. Cell Rep, 2020, 33(13):108571.DOI:10.1016/j.celrep.2020.108571. Cited in this article [1]

[23]	Yang L, Zhang Y. Tumor-associated macrophages:from basic research to clinical application[J]. J Hematol Oncol, 2017, 10(1):58.DOI:10.1186/s13045-017-0430-2. Cited in this article [1]

[24]	Zhang J, Fan J, Zeng X, et al. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment[J]. Acta Pharm Sin B, 2021, 11(3):609-620.DOI:10.1016/j.apsb.2020.10.022. Cited in this article [2]

[25]	Wang J, Zhu N, Su X, et al. Novel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing[J]. Front Immunol, 2024, 14:1264774.DOI:10.3389/fimmu.2023.1264774. Cited in this article [2]

[26]	Prenen H, Mazzone M. Tumor-associated macrophages:a short compendium[J]. Cell Mol Life Sci, 2019, 76(8):1447-1458.DOI:10.1007/s00018-018-2997-3. Cited in this article [1]

[27]	Tacconi C, Ungaro F, Correale C, et al. Activation of the VEGFC/VEGFR3 pathway induces tumor immune sscape in colorectal cancer[J]. Cancer Res, 2019, 79(16):4196-4210.DOI:10.1158/0008-5472.CAN-18-3657. Cited in this article [1]

[28]	Zhao P, Wang B, Zhang Z, et al. Response gene to complement 32 expression in macrophages augments paracrine stimulation-mediated colon cancer progression[J]. Cell Death Dis, 2019, 10(10):776.DOI:10.1038/s41419-019-2006-2. Cited in this article [1]

[29]	Yu X, Wang D, Wang X, et al. CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p[J]. J Exp Clin Cancer Res, 2019, 38(1):32.DOI:10.1186/s13046-018-1014-x. Cited in this article [1]

[30]	Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis:biological roles and clinical therapeutic applications[J]. J Hematol Oncol, 2019, 12(1):76.DOI:10.1186/s13045-019-0760-3. Cited in this article [2]

[31]	Wang Y, Wang W, Wu H, et al. The essential role of PRAK in tumor metastasis and its therapeutic potential[J]. Nat Commun, 2021, 12(1):1736.DOI:10.1038/s41467-021-21993-9. Cited in this article [1]

[32]	Fu LQ, Du WL, Cai MH, et al. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis[J]. Cell Immunol, 2020, 353:104119.DOI:10.1016/j.cellimm.2020.104119. Cited in this article [1]

[33]	Liu M, Liu L, Song Y, et al. Targeting macrophages:a novel treatment strategy in solid tumors[J]. J Transl Med, 2022, 20(1):586.DOI:10.1186/s12967-022-03813-w. Cited in this article [4]

[34]	Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases:regulators of the tumor microenvironment[J]. Cell, 2010, 141(1):52-67.DOI:10.1016/j.cell.2010.03.015. Cited in this article [2]

[35]	Talaat IM, Elemam NM, Zaher S, et al. Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment[J]. Front Med(Lausanne), 2022, 9:955599.DOI:10.3389/fmed.2022.955599. Cited in this article [1]

[36]	Wei C, Yang C, Wang S, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis[J]. Mol Cancer, 2019, 18(1):64.DOI:10.1186/s12943-019-0976-4. Cited in this article [1]

[37]	Phinney BB, Ray AL, Peretti AS, et al. MK2 regulates macrophage chemokine activity and recruitment to promote colon tumor growth[J]. Front Immunol, 2018, 9:1857.DOI:10.3389/fimmu.2018.01857. Cited in this article [1]

[38]	Yin Z, Ma T, Huang B, et al. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1):310.DOI:10.1186/s13046-019-1313-x. Cited in this article [1]

[39]	Lu L, Liu YJ, Cheng PQ, et al. Macrophages play a role in inflammatory transformation of colorectal cancer[J]. World J Gastrointest Oncol, 2021, 13(12):2013-2028.DOI:10.4251/wjgo.v13.i12.2013. Cited in this article [2]

[40]	Jedinak A, Dudhgaonkar S, Sliva D. Activated macrophages induce metastatic behavior of colon cancer cells[J]. Immunobiology, 2010, 215(3):242-249.DOI:10.1016/j.imbio.2009.03.004. Cited in this article [1]

[41]	Suarez-Lopez L, Kong YW, Sriram G, et al. MAPKAP kinase-2 drives expression of angiogenic factors by tumor-associated macrophages in a model of inflammation-induced colon cancer[J]. Front Immunol, 2021, 11:607891.DOI:10.3389/fimmu.2020.607891. Cited in this article [1]

[42]	Bi Y, Shirure VS, Liu R, et al. Tumor-on-a-chip platform to interrogate the role of macrophages in tumor progression[J]. Integr Biol(Camb), 2020, 12(9):221-232.DOI:10.1093/intbio/zyaa017. Cited in this article [1]

[43]	Nocito A, Dahm F, Jochum W, et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts[J]. Cancer Res, 2008, 68(13):5152-5158.DOI:10.1158/0008-5472.CAN-08-0202. Cited in this article [1]

[44]	Xu H, Zhang Y, Peña MM, et al. Six1 promotes colorectal cancer growth and metastasis by stimulating angiogenesis and recruiting tumor-associated macrophages[J]. Carcinogenesis, 2017, 38(3):281-292.DOI:10.1093/carcin/bgw121. Cited in this article [1]

[45]	Luput L, Licarete E, Sesarman A, et al. Tumor-associated macrophages favor C26 murine colon carcinoma cell proliferation in an oxidative stress-dependent manner[J]. Oncol Rep, 2017, 37(4):2472-2480.DOI:10.3892/or.2017.5466. Cited in this article [1]

[46]	Zhang LJ, Huang R, Shen YW, et al. Enhanced anti-tumor efficacy by inhibiting HIF-1α to reprogram TAMs via core-satellite upconverting nanoparticles with curcumin mediated photodynamic therapy[J]. Biomater Sci, 2021, 9(19):6403-6415.DOI:10.1039/d1bm00675d. Cited in this article [1]

[47]	Yin Y, Yao S, Hu Y, et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6[J]. Clin Cancer Res, 2017, 23(23):7375-7387.DOI:10.1158/1078-0432.CCR-17-1283. Cited in this article [1]

[48]	Zhang X, Chen Y, Hao L, et al. Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine[J]. Cancer Lett, 2016, 381(2):305-313.DOI:10.1016/j.canlet.2016.08.004. Cited in this article [1]

[49]	Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer[J]. Cancer Cell, 2015, 27(4):462-472.DOI:10.1016/j.ccell.2015.02.015. Cited in this article [1]

[50]	Binenbaum Y, Fridman E, Yaari Z, et al. Transfer of miRNA in macrophage-derived exosomes induces drug resistance in pancreatic adenocarcinoma[J]. Cancer Res, 2018, 78(18):5287-5299.DOI:10.1158/0008-5472.CAN-18-0124. Cited in this article [1]

[51]	Ma YS, Wu TM, Ling CC, et al. M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B[J]. Mol Ther Oncolytics, 2021, 20:484-498.DOI:10.1016/j.omto.2021.02.005. Cited in this article [1]

[52]	Sahraei M, Chaube B, Liu Y, et al. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response[J]. J Clin Invest, 2019, 129(12):5518-5536.DOI:10.1172/JCI127125. Cited in this article [1]

[53]	Gao C, Hu W, Zhao J, et al. LncRNA HCG18 promotes M2 macrophage polarization to accelerate cetuximab resistance in colorectal cancer through regulating miR-365a-3p/FOXO1/CSF-1 axis[J]. Pathol Res Pract, 2022, 240:154227.DOI:10.1016/j.prp.2022.154227. Cited in this article [1]

[54]	Bhattacharya U, Gutter-Kapon L, Kan T, et al. Heparanase and chemotherapy synergize to drive macrophage activation and enhance tumor growth[J]. Cancer Res, 2020, 80(1):57-68.DOI:10.1158/0008-5472.CAN-19-1676. Cited in this article [1]

[55]	Ziogas DC, Theocharopoulos C, Koutouratsas T, et al. Mechanisms of resistance to immune checkpoint inhibitors in melanoma:what we have to overcome[J]. Cancer Treat Rev, 2023, 113:102499.DOI:10.1016/j.ctrv.2022.102499. Cited in this article [1]

[56]	Molgora M, Esaulova E, Vermi W, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy[J]. Cell, 2020, 182(4):886-900.e17.DOI:10.1016/j.cell.2020.07.013. Cited in this article [1]

[57]	Im JH, Buzzelli JN, Jones K, et al. FGF2 alters macrophage polarization,tumour immunity and growth and can be targeted during radiotherapy[J]. Nat Commun, 2020, 11(1):4064.DOI:10.1038/s41467-020-17914-x. Cited in this article [1]

[58]	Genard G, Lucas S, Michiels C. Reprogramming of tumor-associated macrophages with anticancer therapies:radiotherapy versus chemo-and immunotherapies[J]. Front Immunol, 2017, 8:828.DOI:10.3389/fimmu.2017.00828. Cited in this article [1]

[59]	Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis[J]. J Cancer, 2017, 8(5):761-773.DOI:10.7150/jca.17648. Cited in this article [1]

[60]	Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy[J]. Cell Metab, 2017, 26(1):94-109.DOI:10.1016/j.cmet.2017.06.016. Cited in this article [1]

[61]	Zhang J, Shi Z, Xu X, et al. The influence of microenvironment on tumor immunotherapy[J]. FEBS J, 2019, 286(21):4160-4175.DOI:10.1111/febs.15028. Cited in this article [1]

[62]	DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19(6):369-382.DOI:10.1038/s41577-019-0127-6. Cited in this article [3]

[63]	Maisonneuve C, Tsang DKL, Foerster EG, et al. Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells[J]. Cell Rep, 2021, 34(4):108677.DOI:10.1016/j.celrep.2020.108677. Cited in this article [1]

[64]	Liu C, Yao Z, Wang J, et al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway[J]. Cell Death Differ, 2020, 27(6):1765-1781.DOI:10.1038/s41418-019-0460-0. Cited in this article [1]

[65]	Wang X, Lang M, Zhao T, et al. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+)Treg cells in pancreatic ductal adenocarcinoma[J]. Oncogene, 2017, 36(21):3048-3058.DOI:10.1038/onc.2016.458. Cited in this article [1]

[66]	Wei C, Yang C, Wang S, et al. M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling[J]. Onco Targets Ther, 2019, 12:3051-3063.DOI:10.2147/OTT.S198126. Cited in this article [1]

[67]	Dong Q, Liu X, Cheng K, et al. Pre-metastatic niche formation in different organs induced by tumor extracellular vesicles[J]. Front Cell Dev Biol, 2021, 9:733627.DOI:10.3389/fcell.2021.733627. Cited in this article [1]

[68]	Wang D, Sun H, Wei J, et al. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer[J]. Cancer Res, 2017, 77(13):3655-3665.DOI:10.1158/0008-5472.CAN-16-3199. Cited in this article [1]

[69]	Zhao S, Mi Y, Guan B, et al. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer[J]. J Hematol Oncol, 2020, 13(1):156.DOI:10.1186/s13045-020-00991-2. Cited in this article [1]

[70]	Shao Y, Chen T, Zheng X, et al. Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis[J]. Carcinogenesis, 2018, 39(11):1368-1379.DOI:10.1093/carcin/bgy115. Cited in this article [2]

[71]	Li S, Hao L, Hu X. Biological roles and clinical therapeutic applications of tumor-associated macrophages in colorectal liver metastasis[J]. J Inflamm Res, 2024, 17:8429-8443.DOI:10.2147/JIR.S493656. Cited in this article [1]

[72]	Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology[J]. Nat Rev Cancer, 2023, 23(4):238-257.DOI:10.1038/s41568-022-00547-1. Cited in this article [1]

[73]	Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid[J]. Nature, 2014, 513(7519):559-563.DOI:10.1038/nature13490. Cited in this article [1]

[74]	Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment[J]. Cancers(Basel), 2014, 6(3):1670-1690.DOI:10.3390/cancers6031670. Cited in this article [1]

[75]	Chen TW, Hung WZ, Chiang SF, et al. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1[J]. Cancer Lett, 2022, 543:215795.DOI:10.1016/j.canlet.2022.215795. Cited in this article [1]

[76]	Anderson NR, Minutolo NG, Gill S, et al. Macrophage-based approaches for cancer immunotherapy[J]. Cancer Res, 2021, 81(5):1201-1208.DOI:10.1158/0008-5472.CAN-20-2990. Cited in this article [1]

[77]	Li M, Huang T, Li X, et al. GDC-0575,a CHK1 inhibitor,impairs the development of colitis and colitis-associated cancer by inhibiting CCR2(+) macrophage infiltration in mice[J]. Onco Targets Ther, 2021, 14:2661-2672.DOI:10.2147/OTT.S297132. Cited in this article [1]

[78]	Georgoudaki AM, Prokopec KE, Boura VF, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis[J]. Cell Rep, 2016, 15(9):2000-2011.DOI:10.1016/j.celrep.2016.04.084. Cited in this article [1]

[79]	Nakanishi Y, Nakatsuji M, Seno H, et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+mouse polyps[J]. Carcinogenesis, 2011, 32(9):1333-1339.DOI:10.1093/carcin/bgr128. Cited in this article [1]

[80]	Xu Y, Wang X, Liu L, et al. Role of macrophages in tumor progression and therapy(review)[J]. Int J Oncol, 2022, 60(5):57.DOI:10.3892/ijo.2022.5347. Cited in this article [1]

[81]	Huang Z, Gan J, Long Z, et al. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection[J]. Biomaterials, 2016, 90:72-84.DOI:10.1016/j.biomaterials.2016.03.009. Cited in this article [1]

[82]	Shime H, Matsumoto M, Oshiumi H, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors[J]. Proc Natl Acad Sci U S A, 2012, 109(6):2066-2071.DOI:10.1073/pnas.1113099109. Cited in this article [1]

[83]	Rodell CB, Arlauckas SP, Cuccarese MF, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy[J]. Nat Biomed Eng, 2018, 2(8):578-588.DOI:10.1038/s41551-018-0236-8. Cited in this article [1]

[84]

De Carvalho TG, Lara P, Jorquera-Cordero C, et al. Inhibition of murine colorectal cancer metastasis by targeting M2-TAM through STAT3/NF-kB/AKT signaling using macrophage 1-derived extracellular vesicles loaded with oxaliplatin,retinoic acid,and Libidibia ferrea[J]. Biomed Pharmacother, 2023, 168:115663.DOI:10.1016/j.biopha.2023.115663. Cited in this article [1]

[85]	Halama N, Zoernig I, Berthel A, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients[J]. Cancer Cell, 2016, 29(4):587-601.DOI:10.1016/j.ccell.2016.03.005. Cited in this article [1]

[86]	Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization:enabling diversity with identity[J]. Nat Rev Immunol, 2011, 11(11):750-761.DOI:10.1038/nri3088. Cited in this article [1]

[87]	Weigert A, Sekar D, Brüne B. Tumor-associated macrophages as targets for tumor immunotherapy[J]. Immunotherapy, 2009, 1(1):83-95.DOI:10.2217/1750743X.1.1.83. Cited in this article [1]

[88]	Shen X, Zhou S, Yang Y, et al. TAM-targeted reeducation for enhanced cancer immunotherapy:mechanism and recent progress[J]. Front Oncol, 2022, 12:1034842.DOI:10.3389/fonc.2022.1034842. Cited in this article [1]

[89]	Zhu M, Bai L, Liu X, et al. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages[J]. J Immunother Cancer, 2022, 10(12):e005610.DOI:10.1136/jitc-2022-005610. Cited in this article [1]

[90]	Limagne E, Thibaudin M, Nuttin L, et al. Trifluridine/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages[J]. Cancer Immunol Res, 2019, 7(12):1958-1969.DOI:10.1158/2326-6066.CIR-19-0228. Cited in this article [1]

[91]	Qiao T, Yang W, He X, et al. Dynamic differentiation of F4/80+tumor-associated macrophage and its role in tumor vascularization in a syngeneic mouse model of colorectal liver metastasis[J]. Cell Death Dis, 2023, 14(2):117.DOI:10.1038/s41419-023-05626-1. Cited in this article [1]

[92]	Razak AR, Cleary JM, Moreno V, et al. Safety and efficacy of AMG 820,an anti-colony-stimulating factor 1 receptor antibody,in combination with pembrolizumab in adults with advanced solid tumors[J]. J Immunother Cancer, 2020, 8(2):e001006.DOI:10.1136/jitc-2020-001006. Cited in this article [2]

[93]	Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer:mechanisms and emerging therapeutics[J]. Trends Pharmacol Sci, 2023, 44(4):222-236.DOI:10.1016/j.tips.2023.01.003. Cited in this article [1]

[94]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.DOI:10.3322/caac.21834. Cited in this article [1]